Leaders in Pharmaceutical Business Intelligence (LPBI) Group

All Contributors to Leaders in Pharmaceutical Business Intelligence (LPBI) Group

• Aviva Lev-Ari, PhD, RN, Director and Founder
• Members of the Board
• Senior Editors
• Experts, Authors, Writers (EAWs)
• Business Development & Private Equity Investment
• Scientific Delegation Members & Patent Holders
• Inventors: Biologics
• Inventors: Medical Devices
• PostDoctorants: Computer Science, Pharmaceutical Sciences, Biological Sciences
• Research Assistants
• Research Associates

 

Affiliations of our 13 Final Improvement Team (FIT) members

• Medical Doctors: Dr. Larry H. Bernstein (retired-inactive), Dr. Justin Pearlman (Central Maine Medical Center), Dr. Jason S. Zielonka, MD, AFACC
• Doctors of Philosophy: Dr. Justin Pearlman, Dr. Stephen Williams, Dr. Sudipta Saha, Dr. Irina Robu and Dr. Aviva Lev-Ari, Adam Sonnenberg, PhD, BU’20 (inactive), Dr. Joel Shertok, Ofer Markman, PhD
• Professors in Academia: Prof. Marcus W. Feldman (Stanford University), Prof. Stephen J. Williams (Temple University), Prof. Sudipta Saha (Amity University Noida, Uttar Pradesh, India), Dr. Irina Robu (Windsor, Ontario, Canada)
• Executives in Biotechnology and Information Technology Industries: Dr. Joel Shertok, Rick Mandahl, MBA, Americas (business development consultant in emerging technologies with Biotech, Information Technology focus), Gail S. Thornton, M.A., PhD(c), (Merck & Co., USA), communications consultant, published author on health, wellness, communications strategy
• Research Assistants: Alex Crystal (III) and Devanshi S. Bhangle (II)

BIOS of LPBI TEAM MEMBERS JOINING THE EXIT

 

• Advisor and Member of the Board – Marcus Feldman, PhD, Member of the Board, Scientific Counsel: Life Sciences

MARCUS WILLIAM FELDMAN

Professor, Department of Biology, Stanford University

327 W Campus Drive, Stanford, CA 94305-5020

mfeldman@stanford.edu. Tel.: 650-725-1867

1. Professional Preparation

University of Western Australia        Mathematics                           B.Sc., 1964

Monash University, Australia           Mathematics                           M.Sc., 1966

Stanford University                          Mathematical Biology             Ph.D., 1969

 

2. Appointments

2013–         Co-director, Stanford Center for Computational, Evolutionary and Human Genomics

2005–         Director, Center for Complexity Studies, Xi’an Jiaotong University, Xi’an, China

1993–         Burnet C. and Mildred Finley Wohlford Professor of Biology, Stanford

1986–         Director, Morrison Institute for Population and Resource Studies, Stanford

1977–         Professor, Department of Biological Sciences, Stanford

1974–1977  Associate Professor, Department of Biological Sciences, Stanford

1971–1974  Assistant Professor, Department of Biological Sciences, Stanford

1970–1971  Lecturer, Department of Mathematics, La Trobe University, Australia

 

3. Honors

• Elected Fellow, American Academy of Arts and Sciences, 1987
• “Paper of the Year”, The Lancet, 2003.
• Doctor Philosophiae Honoris Causa, Hebrew University Jerusalem, 2005
• Honorary Professor, Xi’an Jiaotong University, 2005
• Doctor Philosophiae Honoris Causa, Tel Aviv University, 2010
• Elected member, American Philosophical Society, 2011
• Dan David laureate, 2011
• Elected member, National Academy of Sciences, 2013
• Kimura Motoo Award in Human Evolution, 2016
• Alumni lifetime achievement award, University of Western Australia, Faculty of Engineering, Computer Science and Mathematics, 2016
• Allan V. Cox Medal for Fostering Undergraduate Research at Stanford, 2017

4. Biography

Marcus Feldman, Ph.D., is the Wohlford Professor of Biology at Stanford University and External Professor at the Santa Fe Institute. He directs the Morrison Institute for Population and Resource Studies and is co-director of Stanford’s Center for Computational, Evolutionary and Human Genomics. Feldman’s specific areas of research include the evolution of complex genetic systems that can undergo both natural selection and recombination, the evolution of modern humans using models for the dynamics of molecular polymorphisms, especially DNA variants, cultural evolution, and the evolution of learning as one interface between modern methods in artificial intelligence and models of biological processes, including communication. He is the author of more than 650 scientific papers and ten books on evolution, ecology, mathematical biology, and demography.

 

• Member of the Board and Expert on Cancer Biology, Immunotherapy, Pharmacology, Toxicology – Stephen J. Williams, Member of the Board and Senior Editor, PhD Pharmacology, BSc Toxicology

 

STEPHEN J. WILLIAMS, Ph.D.

Tel: 215 487 0259 (h) 610 331 1016 (c) Email: sjwilliamspa@comcast.net

For the onset of my scientific career I entered one of the first undergraduate toxicology programs in the country, at the Philadelphia College of Pharmacy & Science, and trained in various methodologies in toxicology and pharmacology, including research into effects of leukotrienes and leukotriene antagonists on gastrointestinal motility. I continued with my research training at the University of Pennsylvania Institute for Environmental Medicine, studying the effects of hyperbaric oxygen, and free radicals on lung function and the pathology of Sudden Infant Death Syndrome. I subsequently received my PhD in Pharmacology from Temple University, with my thesis, under Dr. Michael Sirover, involving the biochemical and pharmacologic effects on non-canonical protein functions in metabolism and DNA repair. Afterward, I continued with postdoctoral training in the Department of Pharmacology under an NCI-PRAT fellowship and in the Ovarian Cancer Program in the laboratory of Dr. Thomas Hamilton. My research involved determination of mechanisms of cisplatin resistance in ovarian cancer, discovering genes causal in early ovarian oncogenesis, and development of animal ovarian tumor models useful for determining ovarian cancer driver genes, determining chemotherapeutic efficacy, and development of imaging and surrogate tumor biomarker methods for detection of ovarian tumor burden in in-vivo ovarian cancer models. To this end, I developed one of the first, and patented, porcine ovarian tumor models, and with colleagues, additional models to measure intraperitoneal ovarian cancer using both surrogate tumor markers and MRI imaging methodology useful for chemotherapeutic evaluation.

As scientific research and information was entering a new explosive age of massive data, I decided to assist Dr. Aviva Lev Ari in her venture Leaders in Pharmaceutical Business Intelligence, in developing a methodology of scientific curation, in collaboration with Dr. Larry Bernstein and a worldwide network of expert scientists and clinicians.   This effort culminated in the development of an influential web 2.0 platform for the curation, organization, and dissemination of scientific and biomedical findings in addition of the creation of 16 medical e-books on multiple topics. As such I became senior editor on two volumes, an e-book series on Cancer and a series on Genomics.

Concurrently I was designated an adjunct professor in Temple University College of Science & Technology, teaching a course on Cell Signaling and Cancer Biology, as well as an associate professor in the Sbarro Health Research Organization where I head the grants department including grants management and administration. Currently I also decided to continue my research efforts into understanding events causal in early oncogenesis and joined the research organization ISOPROG, where we have been researching autocrine growth factor loops involved in the malignant phenotype in mesothelioma and other cancer types.

As a result of the aforementioned endeavors, I have multiple peer-reviewed publications and book chapters as well as whole books in the fields of cancer, genomics, and personalized oncology. In addition, I am a frequent reviewer for such journals such as Cancer Research, Cancers, the Journal of Cellular Physiology, and others.

 

 

Founder and Editor-in-Chief

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Boston, NJ, Salt Lake City, Israel, Maine, New Delhi, Palo Alto, Philadelphia, Toronto, Newark, DE

 

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston Editor-in-Chief

http://pharmaceuticalintelligence.com

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN

SkypeID: HarpPlayer83  LinkedIn Profile  Twitter Profile

 

1. Professional Preparation

UNIVERSITY OF CALIFORNIA, BERKELEY

Ph.D, 1978 – 1983

Industrial Organization Economics, Industrial Systems-Economic Geography, College of Letters & Science

Grade 3.75/4.00

Activities and Societies: ASA, ORSA

Stanford University Graduate School of Business

Exchange Program with UC Berkeley 11 courses of MBA Program

Area: Organization Behavior

1980 – 1981

Northeastern University

PreMed, 2005 – 2005

Biological and Biomedical Sciences, Four semesters, course load: 15 courses 2005

Northeastern University

Nursing, RN, 2005 – 2007

Bouve College of Health Sciences, School of Nursing, Four semesters of Independent Research in Cardiovascular Pharmacotherapy with Prof. Paul Abourjaily

Activities and Societies: ANA, MARN

Hebrew University of Jerusalem

BA, MA

Urban Planning, Economic Geography

GPA 95/100

1970 – 1976

Activities and Societies: Israel Poets Association

HUGGIM – High School, Mount Carmel, Haifa, Israel

Baccalaureate in Economics and Political Sciences, 93/100

1964 – 1968

 

2. Appointments

• Scientific and Medical Affairs Chronological CV
• Technology Executive, Methodology and Decision Scientist, Functional CV
• Contributions to Design of Algorithm-based Decision Support Systems
• Technical Contributions in the Domain of Electronic Commerce Analytics: Aviva Lev-Ari, Ph.D.
• HealthCare Delivery – Long Term Post Acute Care Nursing Management CV

3. Nominations for Awards & Honors

• Nominee for 2020 Campanile Excellence in Achievement Award. This award recognizes an alumnus/a whose remarkable professional lifetime achievements reflect the excellence of a UC Berkeley education. Nominator:  Sheila M. Puffer(UC, Berkeley, PhD’84).

Past Recipients

https://awards.berkeley.edu/achievement-awards

The recipients will be formally presented with their awards at Berkeley Charter Gala on May 14, 2020.

• On 3/31/2018, Dr. Lev-Ari, PhD, RN was nominated for the 2018 Yidan Foundation Prize

https://yidanprize.org/

Per request for supporting material, the following was submitted to the nominator, Prof. Marcus W. Feldman of Stanford University, Department of Biology.

• Nomination for 2018 Yidan Prize, recognition in the field of medical education: development of curation methodologies for scientific content – 2018 Nominee, Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2018/10/21/nomination-for-2018-yidan-prize-recognition-in-the-field-of-medical-education-development-of-curation-methodologies-for-scientific-content-2018-nominee-aviva-lev-ari-phd-rn/

• 8/17/2018, Dr. Lev-Ari, PhD, RN was contacted by the President elect of the Massachusetts Academy of Sciences (MAS), Prof. Katya Ravid of Boston University, School of Medicine, to join MAS in the role of Liaison to the Biotechnology and eScientific Publishing industriesfor the term of August 2018-July 2021. In the MAS, Dr. Lev-Ari serve as Board member, Fellow, and Advisor to the Governing Board.

http://www.maacadsci.org

MAS FELLOWS 

GOVERNING BOARD

ACTIVITIES

• On 12/7/2018, Dr. Lev-Ari was nominated for 2019 Berkeley Alumna of the Year Achievement Award

2019 Awardees

https://awards.berkeley.edu/achievement-awards

 

4. Biography

PharmaceuticalIntelligence.com

Launched on 4/28/2012

On 3/3/2020 this Open Access Scientific Journal has 1,723,362 e-Readers

 

Our portfolio of Intellectual Property (IP) include NINE asset classes

https://pharmaceuticalintelligence.com/2019-vista/

 

Aviva Lev-Ari, PhD, RN serves as

• Administrator of the platform and its architect since 4/2012, the venture inception. # Views by eReaders of Administrator’s posts +430,000
• Is the Launcher of the Website PharmaceuticalIntelligence.com
• Is the IP owner with agreements with each Expert, Author, Writer (EAW)
• Is the Editor-in-Chief of the

1. Journal [com] and of
2. the BioMed e-Series [https://pharmaceuticalintelligence.com/biomed-e-books/]
3. the e-Proceedings https://pharmaceuticalintelligence.com/press-coverage/

• Is the Co-Editor of several volumes in each series, except Series C: Cancer
• Is the Publisher of +3,300 of the 5,700 articles in the Journal
• Is the Developer of the Methodology of Curation for Pharmaceutics and Media top article 17,000 views, Several of Aviva’s articles fetch +10,000 views
• Is Developer of the Methodology of electronic Table of Contents (eTOCs) creation and was involved in the population of all eTOCs by Expert Editors that culled articles from the journal’s research categories to create ONE of a kind an eTOCs for each volume [except Series C: Cancer]
• Is Developer of the Methodology of Real Time Press Coverage of Top Biotech Conferences using social media and the ONE key stroke method for generation of the e-Proceedings.
• Is The Producer of 60 of the 70 Conference e-Proceedings in the venture’s Archive of Press Coverage of Biotech and Medical Conferences

https://pharmaceuticalintelligence.com/press-coverage/part-two-list-of-biotech-conferences-2013-to-present/

• Lev-Ari is the creator of THREE intellectual property asset classes in Media & Healthcare (pharmaceutical, medicine, medical devices & diagnostics, bioinformatics). The three archives are ready for Text Analysis & Text Mining by AI, ML and NLP algorithms
• Is the developer of the methodology for Real Time Press coverage with social media
• The archive of 70 eProceeding documents was produced at 70 Biotech and Medical Conferences covered in Real Time during attendance. Each Conferences yielded on average 4 – 5 new curations in the Journal
• Is the creator of the 30 Collections of Tweets she posted in real time at 60 of the 70 Biotech and Medical Conferences listed in

https://pharmaceuticalintelligence.com/press-coverage/part-three-conference-eproceedings-deliverables-social-media-analytics/

• Is the presenter of the Twitter Analytics of LPBI Group’s social media coverage of each conference by @pharma_BI and by @AVIVA1950

For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics  [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers]

 

Our Team of Experts

• Chief Scientific Officer 

Dr. Jason Sol Zielonka, MD, AFACC

Fishers IN 4604-0

Jasonz.MIT@gmail.com

Tel.: (917) 856-4852

LinkedIn: http://www.linkedin.com/in/jason1z

 

BIO

 

1. Professional Preparation

• Massachusetts Institute of Technology  

B.S., 1970   Electrical Science & Engineering

• Yale University School of Medicine

M.D., 1974   Medicine

• University of Minnesota School of Medicine, Minneapolis

Internship, Surgical, 1974-75

Residency, Neurosurgery, 1975-76

Residency, Diagnostic Radiology, 1976-78

• Harvard University School of Medicine, Joint Program in Nuclear Medicine

Post-Doctoral Fellowships (Clinical, Research), 1978-81

 

2. Appointments

• Adjunct Faculty, Purdue University (August 2012 – present)

Executive Management, Biotechnology & Entrepreneurship Programs

• Eli Lilly & Company, Inc, Indianapolis, IN (August 2012 – December 31, 2017)

Medical Fellow, Global Patient Safety, Diabetes & AutoImmune Business Units (2012- March 2015)

Medical Fellow, Global Patient Safety, Oncology (March 2015 – Dec 2017)

• Questcor Pharmaceuticals Inc, Union City, CA (2010-2010) Senior Vice President & Chief Medical Officer
• Ortho-McNeil Janssen Scientific Affairs (OMJSA), Titusville, NJ (2005-2010) Senior Medical Director, Trial Methodology, Data Generation
• Pfizer, Inc., New York, NY (2002-2005) Senior Medical Director
• Pfizer Global Pharmaceuticals (PGP), NYC, NY (Jan 2004-Aug 2005)
• Pfizer Global Research & Development (PGRD), Sandwich, UK (Jan 2002-Dec 2003) Early Therapeutic Area Lead (ETAL), CV & Non-sexual Indications, PDE-5i
• DuPont Pharmaceuticals, Inc., Wilmington, DE (2000-2002), Senior Medical Director & Head, Cardiovascular Clinical Research®)
• Independent Consultant, Philadelphia, PA (1998-2000)
• PREMIER RESEARCH WORLDWIDE, Philadelphia, PA (1995-1998), Senior Vice President, Scientific and Regulatory Services
• NYCOMED R&D INC., Collegeville, PA (1993-1995) (formerly Diagnostic Imaging Division, Sterling-Winthrop Inc. [SWPRD]) Director, Medical & Scientific Affairs
• NOVO NORDISK PHARMACEUTICALS, INC., Princeton, NJ (1992-1993), Director, Clinical Development
• BRISTOL-MYERS SQUIBB COMPANY, INC., Princeton, NJ (1987-1992)
• Pharmaceutical Research Institute (1990-1992), Director, Cardiovascular Clinical Research
• Squibb Diagnostics (1987-1990), Medical Director, Worldwide Clinical Research

• MEDICAL COLLEGE OF WISCONSIN, Milwaukee, WI (1983-1987)

1. Chief, Nuclear Medicine Service, Veterans Administration Medical Center
2. Assistant Professor, Dept of Radiology, Division of Nuclear Medicine

• MASSACHUSETTS GENERAL HOSPITAL, Boston, MA (1981-1983)

1. Staff Physician, Nuclear Medicine Division
2. Instructor, Radiology (Harvard Medical School)
3. Intern, Department of Surgery (1974-1975)
4. Resident, Department of Neurological Surgery (1975-1976)
5. Resident, Department of Diagnostic Radiology (1976-1978)

• Harvard Medical School, Boston, MA (1978-1981), Fellow, Cardiovascular Nuclear Medicine

3. Honors & Certifications

Associate Fellow, American College of Cardiology (ACC) (1991)

Certification, American Board of Nuclear Medicine (1981)

Diplomate, National Board of Medical Examiners (1975)

Tau Beta Pi (National Honorary Society) (1969)

Sigma Xi (National Scientific Research Honorary Society) (1969)

Eta Kappa Nu (National Electrical Engineering Honorary Society) (1968)

 

Listed in:

Directory of Medical Specialists Who’s Who in the East

Who’s Who Registry of Global Business Leaders

 

4. Biography

Dr Zielonka retired from Eli Lilly & Company at the end of December 2017, completing a 30 year career in the pharmaceutical industry and entering the next phase of his career.

Dr Zielonka has held positions with several biopharmaceutical and consulting organizations, including Bristol-Myers Squibb, Novo Nordisk, Sterling Winthrop, Dupont Pharma, Pfizer (in the UK and US), and Johnson & Johnson. He was also a full-time consultant to FDA, helping implement and manage the current Adverse Event Reporting System (AERS) and serving as FDA’s first head of clinical coding and evaluation. The roles he has held have included global patient safety, clinical research, medical affairs and exploratory medicine. During this period, he led or participated in six successful first-in-class product development teams.

 

• Justin D. Pearlman, AB, MD, ME, PhD, MA, FACC, Expert, Author, Writer, Editor & Content Consultant for e-SERIES A: Cardiovascular Diseases

• Irina Robu, PhD, Material Scientist and Business Developer for Materials Segment of Manufacturing Industry

Expertise in Tissue engineering, drug delivery, Biomaterials and 3D BioPrinting

Irina Robu earned her PhD in Chemical Engineering with minor in Biomedical Engineering, MS and BSc in Chemical Engineering from Wayne State University and BSc in Chemistry from University of Windsor. My decision to pursue graduate studies in tissue engineering research was a natural result of my passion for chemistry, engineering, medicine and life sciences. During the PhD, she worked on assessing the growth, proliferation, adhesion, and spreading of SMCs and ECs on covalently immobilized GAG-chitosan material in-vitro, created and evaluated seeding efficiency of GAG-chitosan vascular graft and designed and evaluate a pulsatile bioreactor system for long-term 3D culture of large diameter tissue engineered constructs with efficient cell seeding, cell distribution and viability. After PhD, she worked at Indiana University-Purdue University she conducted independent research to examine the osteogenic differentiation potential of mesenchymal stem cell and dental pulp, endometrial stem cells to test its feasibility for bone tissue engineering applications and then worked as Patent Researcher at London IP and Writer/Editor at LPBI.

 

• Sudipta Saha, PhD, Expert, Author, Writer, Co-Editor, Series D, Volume 2: Infectious Diseases

Expertise in Bio Instrumentation, Reproductive biology and Endocrine genomics

• Amity Institute of Physiology and Allied Sciences (AIPAS),
• Amity University, Noida, Uttar Pradesh,
• Sector-125, Noida – 201313
• Mobile: +91 9830079019, +91 9810349961
• E-Mail: sudiptasaha49@yahoo.co.in, sudiptasaha1977@gmail.com, ssaha2@amity.edu

Research interests are

• Reproductive Biology (Specifically sperm motility) and
• Cell Biology (Specifically cell cycle regulation).

Education

• Post Doc from Chang Gung University, Taiwan
• PhD in Life Science from CSIR-Indian Institute of Chemical Biology (IICB) / Jadavpur University
• BSc and MSc in Physiology from Calcutta University

Appointments

• Assistant Professor (III) of Physiology at Amity University Noida Extramural Project Grant of Rs. 3 million from DST-SERB (Science and Engineering Research Board-Start-up Research Grant).
• Author/Reporter/Curator for pharmaceuticalintelligence.com LPBI Group, Boston since 2012.
• Pool Scientist at CSIR-IICB

Publications

• 14 Journal Publications,
• 4 Book Chapters,
• 7 e-Books,
• 1 Granted Patent,
• 5 Press Mentions

Awards

Recipient of 4 Awards during PhD.

 

• Alex Crystal – Research Assistant III – Data Scientist

(617) 686-8810 • acrystal@u.rochester.edu

• Devanshi S. Bhangle, Research Assistant II – CS & Biology

(438) 924-4845 • devanshi.bhangle@mail.mcgill.ca

  

Our Team of Business Executives

• Business Development

Dr. Joel Shertok; jshertok@processindconsultants.com   302-562-9759

Executive Biography

Dr. Joel Shertok is a senior level executive who has over 40 years of experience in the Chemical Process and Materials industries. His track record is characterized by: merger and acquisition experience, development of new product lines, creation of new business ventures, creation/motivation of new business teams, and international investigations of novel technologies.

Previously, Dr. Shertok has been a Research Fellow at Rochester Institute of Technology. He has held senior technical and managerial positions at Rochester Midland Corporation (formulated products and sanitizers, Graver Technologies (filtration and purification), Pall-Gelman Corporation (membrane filtration and water purification), Amoco Corporation (Carbon fiber composites and BioTechnology), and Union Carbide (specialty chemicals).

Dr. Shertok holds numerous patents in membrane technology, carbon purification, and in industrial food service cleaners. He is currently President of Process Industries Consultants, a chemical engineering consulting firm located in Newark, Delaware.

 

Richard A. Mandahl­­, Business Development, Merger and Acquisitions, Exit Management

Richard A. Mandahl, MBA

Salt Lake City, UT 84121 • 801-243-5937

rmandahl@gmail.com

linkedin.com/in/rick-mandahl-557260

 

Health and Information Technology Business Development Advisor

Rick Mandahl is engaged in helping the innovative Leaders in Pharmaceutical Business Intelligence (LPBI) Group evolve its scalable and reproducible business model, which includes maintaining a growing portfolio of eJournal, eLibrary, eConference proceedings and supporting advertising offers to support its current 1.5 million followers. LPBI Group aspires to be a global and disruptive alternative to cost-prohibitive medical and scientific publications, as well as a resource for translational research pursuits across multiple disciplines. LPBI Group is a company with virtual Knowledge-as-a-Service that can be organized, aggregated and distributed in novel ways anywhere from the Cloud. From a core and growing archive of specialized, technical content and new information products and services, the offerings of LPBI Group are journals, books and conference proceedings, which can serve as subject matter for podcasts for nontraditional and traditional consumers of technical content, including underserved populations anywhere. The core objective of containing the explosion of scientific and medical information while protecting against information obsolescence is well served by the current LPBI Group model as the company strives to position itself for the right strategic buyer. MORE…

 

Dr. Ofer Markman, PhD

oferm2015@gmail.com   +972-523-275720   Haifa, Israel

Dr. Markman is a serial entrepreneur with over 20 years of experience serving as CEO or CXO for several companies in the biotechnology, technology, and food technology space. He has raised over $70M in venture capital financing for companies that have had various successful exits, including some companies that remain private and others that have had an IPO. Most notably he was a founding partner of Procognia that has raised over $50M in 2007.

Dr Markman was a lecturer of Glycotechnology at the Ort Braude Engineering College  and is leading a Science internship program reaching its 80 interns in 3 years land-mark goal

Ofer Published articles and invented multiple patents, Products he has led to markets were sold at over 8 digit dollars of revenue worldwide. As a leader in acceleration plans Dr Markman assisted dozens of entrepreneurs and young companies reach their business goals.

Dr. Markman holds a PhD in Chemistry from Boston College, and worked with Novel Laureate Ada Yonath for his Master’s Degree.

 

• Marketing Communications and Medical Writing

Gail S. Thornton, PhD(c), Contributing Editor, Author and Medical Writer

135 Hillside Road, Chester, New Jersey 07930

908-879-9295 (Home) 908-392-3420 (Mobile)

gailsthornton@yahoo.com; gst@worldviewcomms.com 

Gail S. Thornton, M.A. is founder of Worldview Communications, a global communications consultancy which partners with clients in pharmaceuticals, health care and biotechnology, such as Merck Animal Health and IM HealthScience, among others.

Previously, she was vice president/head of communications for the Emerging Markets Region for Merck, where she built and led a team of regional and country communicators, developed internal and external communications and provided strategic counsel and support to senior executives. Previously, at Schering-Plough, she was vice president, International Communications, responsible for building a team of communicators in all international markets, and handling internal and external communications, product communications and advocacy development, and company image and reputation. Ms. Thornton was senior director, public relations and advocacy development, at Pfizer, Inc., senior director, public relations and advocacy development at Pharmacia Corporation and spent 20 years Bristol-Myers Squibb in positions including international product relations, brand image and reputation management and global employee communications.

Ms. Thornton holds a B.A. in Journalism from Rider University, an M.A. from the Whitehead School, and is completing a Ph.D. in Health Sciences at Seton Hall. She is a member of the Foreign Press Association and the International Public Relations Association.

She was awarded the 2007 Distinguished Alumna Service Award for Leadership from the Whitehead School and was awarded the 2018 Atlas Award for Lifetime Achievement in Public Relations by the Public Relations Society of America. She is the past recipient of the Tribute to Women in Industry Achievement Award.

She is a published author on topics relating to health and wellness, international communications, and emerging markets in the Journal of International Relations and Diplomacy, Global Health Governance online journal, PR Strategist, Frontline magazine of the International Public Relations Association and Pharmaceutical Executive magazine, as well as The Huffington Post and Thrive Global.

She authored a book chapter on the value of employee engagement in a Portuguese communications textbook, Ensaios Comunicaҫão com Empregados (2014). She co-edited and authored The Voices of Patients, Hospital CEOs, Health Care Providers, Caregivers and Families: Personal Experience with Critical Care and Invasive Medical Procedures, an e-book on patient-centered medicine (2017) offered on Amazon/KindleDirect through Leaders in Pharmaceutical Business Intelligence, an online scientific journal. She co-edited and authored a communications textbook, Strategic Employee Communication: Building a Culture of Engagement by Palgrave Macmillan (2018).

 

This page has the following sub pages.

• Aviva Lev-Ari, PhD, RN, Director and Founder
• Members of the Board
• Senior Editors
• Experts, Authors, Writers (EAWs)
• Business Development & Private Equity Investment
• Scientific Delegation Members & Patent Holders
• Inventors: Biologics
• Inventors: Medical Devices
• PostDoctorants: Computer Science, Pharmaceutical Sciences, Biological Sciences
• Research Assistants
• Research Associates